Pharmacologist
USFDA, Maryland
Dr. Kadavil received his Ph.D. in Molecular Pharmacology and Experimental Therapeutics from the University of Maryland Baltimore, School of Medicine. Following his Ph.D., he joined the FDA as a pharmacologist. Dr. Kadavil first worked in the Office of Scientific Investigations (OSI) - Division of Bioequivalence & Good Laboratory Practice at CDER. During his 8 years at OSI, he conducted both foreign and domestic bioanalytical and clinical inspections. His inspections covered bioavailability/bioequivalence, pharmacokinetic, and GLP studies. In 2011, he joined the Division of Human Food Safety (DHFS) at CVM as a pharmacologist, where he conducted reviews of residue chemistry studies and bioanalytical methods, and also directed method trials for the implementation of official methods to determine and confirm drug residues. In 2014, Dr. Kadavil returned to CDER to become the Team Lead for the Collaboration, Risk Evaluation and Surveillance Team (CREST) under the Office of Study Integrity and Surveillance (OSIS). In September 2018, Dr. Kadavil became the Deputy Director for the Division of Generic Drug Bioequivalence Evaluation in OSIS. He then joined the Office of Clinical Pharmacology as a clinical pharmacology reviewer, working on NDA and IND submissions. He currently serves as a pharmacologist in OSIS' risk evaluation program.
Disclosure information not submitted.
Current Regulatory Guidelines for Using HRMS in Bioanalytical Studies
Tuesday, October 22, 2024
10:00 AM – 10:30 AM MT